XML 64 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]
Information regarding the Company’s segments for the year ended December 31, 2019 and 2018 is as follows:
Revenues by segment
 
Year Ended December 31,
(in thousands)
 
2019
 
2018
 
 
 
 
 
Medical Devices
 
$
30,742

 
$
24,652

Strategic Positions
 
—

 
—

Pharmaceutical
 
—

 
—

Income Generating Assets
 
(36
)
 
7,376

Total revenues
 
$
30,706

 
$
32,028

________________
The table above excludes revenues related to discontinued operations. See Note 3, Discontinued Operations Classified as Assets Held for Sale, for additional information.

(Loss) income by segment
 
Year Ended December 31,
(in thousands)
 
2019
 
2018
 
 
 
 
 
Medical Devices
 
$
(5,230
)
 
$
(5,086
)
Strategic Positions
 
28,758

 
—

Pharmaceutical (1)
 
(19,048
)
 
(98,368
)
Income Generating Assets (1)
 
(74,891
)
 
34,595

Total net (loss) income
 
$
(70,411
)
 
$
(68,859
)
________________
(1) The (Loss) income by segment presented above includes amounts related to both continuing and discontinued operations. See Note 3, Discontinued Operations Classified as Assets Held for Sale, for additional information.

Long-lived assets by segment
 
Year Ended December 31,
(in thousands)
 
2019
 
2018
 
 
 
 
 
Medical Devices
 
$
2,435

 
$
3,545

Strategic Positions
 
—

 
—

Pharmaceutical (1)
 
2,960

 
3,682

Income Generating Assets
 
125

 
160

Total long-lived assets
 
$
5,520

 
$
7,387

________________
(1) The amounts above include Property and Equipment in the Pharmaceutical segment classified as Assets held for sale. See Note 3, Discontinued Operations Classified as Assets Held for Sale, for additional information.

The operations for the Medical Devices segment are primarily located in the United States and the operations for the Pharmaceutical segment are primarily located in Italy, Ireland and the United States.